Percentage of Participants With Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) (CMV Viremia Clearance) at Week 8 [Time Frame: At Week 8]
Percentage of Participants With Achievement of CMV Viremia Clearance and CMV Infection Symptom Control at Weeks 8, 12, 16, and 20 [Time Frame: At Weeks 8, 12, 16 and 20]
Percentage of Participants With Achievement of CMV Viremia Clearance and CMV Infection Symptom Control at Week 8 (After Completion of 8 Weeks Therapy) [Time Frame: At Week 8]
Percentage of Participants With Achievement of CMV Viremia Clearance and CMV Infection Symptom Control After Completion of 8 weeks Therapy Followed by Maintenance of This Treatment Effect Through Weeks 12, 16 and 20 [Time Frame: At Weeks 12, 16 and 20]
Percentage of Participants With Recurrence of CMV Viremia During the First 8 Weeks and Through Week 12 to Week 20 [Time Frame: From first dose of study drug up to Week 8, and through Week 12 to Week 20]
Percentage of Participants With Recurrence of CMV Viremia During on Treatment and off Treatment [Time Frame: From first dose of study drug up to Week 8 (on treatment) and Week 20 (off treatment)]
Percentage of Participants With Recurrence of CMV Viremia Requiring Alternative Treatment After Achieving CMV Viremia Clearance at Study Week 8 [Time Frame: At Week 8]
Percentage of Participants With Mutations in the CMV Genes Conferring Resistance to Maribavir [Time Frame: Up to Week 20]
Number of Participants With All-cause Mortality During the Study [Time Frame: Up to Week 20]
Maximum Observed Plasma Concentration (Cmax) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8, and 12 hours post-dose]
Time to Reach Cmax (Tmax) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Minimum Observed Plasma Concentration (Cmin) for Maribavir [Time Frame: Pre-dose and at Weeks 1, 4, and 8]
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration Area (AUC0-t) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Area Under the Plasma Concentration-Time Curve Over 1 Dosing Interval of 12 Hours (AUC0-tau) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Half -life (t1/2) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Terminal Elimination Rate Constant (Lambda z) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Apparent Volume of Distribution (Vz/F) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
Apparent Oral Clearance (CL/F) at Steady State for Maribavir [Time Frame: Week 1, Day 7: Pre-dose, 0.5, 1.5, 3, 4, 6, 8 and 12 hours post-dose]
